培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效观察

Clinical Observation of Pemetrexed Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer

目的观察培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效及不良反应。方法将我院自2007年1月至2010年5月间收治的晚期非小细胞肺癌患者72例,随机分为观察组和对照组。观察组采用培美曲塞联合顺铂的化疗方案,对照组采用多西他赛联合顺铂的化疗方案。观察2组化疗后的疗效、无进展生存时间、总生存时间以及不良反应等。结果观察组患者CR率8.3%、PR率38.9%、总缓解率47.2%,与对照组患者的CR率(5.6%),PR率(36.1%)以及总缓解率(41.7%)相比,差异均无统计学意义(P>0.05)。2组患者无进展生存时间与总生存时间差异均无统计学意义(P>0.05)。观察组白细胞减少和消化道反应的发生率均显著低于对照组(P<0.05)。结论培美曲塞联合顺铂是晚期非小细胞肺癌有效的治疗方法,不良反应小,患者易于耐受。

Objective To observe the efficacy and toxicities of pemetrexed combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer.Methods From January 2007 to May 2010,72 patients with advanced non-small cell lung cancer in our hospital was randomly divided into observation group and control group.Pemetrexed combined with cisplatin was used in observation group and docetaxel combined with cisplatin was used in control group.The efficacy,time to progression,overall survival time and adverse reactions were observed in each group.Results The CR rate was 8.3%,PR rate was 38.9%,and total remission rate was 47.2% in observation group,there were no statistical difference with control group.Time to progression and overall survival time between these two groups had no statistical difference.The leucocytopenia and enteron reactive in observation group were significantly lower than that in control group.Conclusion Pemetrexed combined with cisplatin is an effective and well-tolerated treatment for advanced non-small cell lung cancer.